Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas

NCT06109207 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Dalpiciclib 100mg
DRUG: Dalpiciclib 150mg

Sponsor

West China Hospital